Department of Pediatrics, IGGMC, Nagpur.
Hematology, Apollo Hospitals, Bhubaneswar, India.
Curr Opin Hematol. 2018 May;25(3):171-176. doi: 10.1097/MOH.0000000000000422.
In the past, milder clinical manifestations of sickle cell disease (SCD) have been described from India. However, recent data from some parts of India suggest that the severity of the disease can be compared to that of African phenotypes. This review therefore describes the varied clinical manifestation of SCD, the success of newborn screening programme, prenatal diagnosis and low dose hydroxyurea therapy in India.
The varied clinical manifestations such as anemia, vaso-occlusive crisis, acute chest syndrome, renal involvement, stroke and so on vary from one part of the country to the other and also among different communities of India. Strategies for improving quality of life and controlling of SCD have been suggested. Certain factors other than genetics also play an important role in clinical manifestation of the disorder.
The clinical diversity of SCD is described. The natural history of SCD in India is unfolding from newborn screening programme. The use of low-dose hydroxy urea therapy both in adults and children has brought down the incidences of crisis and provides great relief to the patients. The tailor-made programme for India as regards the control and management has been discussed.
过去曾有研究报道,印度存在镰状细胞病(SCD)的轻度临床表现。然而,来自印度部分地区的最新数据表明,该病的严重程度可与非洲表型相媲美。因此,本综述描述了 SCD 的各种临床表现、新生儿筛查计划、产前诊断和小剂量羟基脲治疗在印度的成功经验。
不同临床表现,如贫血、血管阻塞性危象、急性胸部综合征、肾脏受累、中风等,在印度不同地区和不同社区之间存在差异。已经提出了改善生活质量和控制 SCD 的策略。除遗传因素外,其他因素也在疾病的临床表现中起着重要作用。
描述了 SCD 的临床表现多样性。印度的 SCD 自然史正在通过新生儿筛查计划展开。低剂量羟基脲治疗在成人和儿童中的应用降低了危象的发生率,为患者带来了极大的缓解。针对印度的控制和管理制定了定制方案。